The DOI matches its Crossref record; 136 of the 136 references it cites were found in a registry or an index.
Mechanisms of killing by anti-CD20 monoclonal antibodies
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Walport, M. J. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441406 · Cited by 2,927
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768
McLaughlin, P., Grillo-López, A. J., Link, B. K., Levy, R., Czuczman, M. S., Williams, M. E., Heyman, M. R., Bence-Bruckler, I., White, C. A., Cabanillas, F., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2825 · Cited by 2,755
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
Edwards, J. C. W., Szczepański, L., Szechiński, J., Filipowicz-Sosnowska, A., Emery, P., Close, D. R., Stevens, R. M., & Shaw, T. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032534 · Cited by 2,623
Wiklund, R. A., & Rosenbaum, S. H. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710163371606 · Cited by 2,149
Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
Reff, M., Carner, K., Chambers, K., Chinn, P., Leonard, J., Raab, R., Newman, R., Hanna, N., & Anderson, D. (1994) · Blood · doi:10.1182/blood.v83.2.435.435 · Cited by 1,999
Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P., & Watier, H. (2002) · Blood · doi:10.1182/blood.v99.3.754 · Cited by 1,900
Anti-Inflammatory Activity of Immunoglobulin G Resulting from Fc Sialylation
Kaneko, Y., Nimmerjahn, F., & Ravetch, J. V. (2006) · Science · doi:10.1126/science.1129594 · Cited by 1,754
Ravetch, J. V., & Bolland, S. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.275 · Cited by 1,657
Feugier, P., Van Hoof, A., Sebban, C., Solal-Celigny, P., Bouabdallah, R., Fermé, C., Christian, B., Lepage, E., Tilly, H., Morschhauser, F., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.131 · Cited by 1,486
Walport, M. J. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104123441506 · Cited by 1,481
Role of Bcl-2 family proteins in a non-apoptotic programmed cell death dependent on autophagy genes
Shimizu, S., Kanaseki, T., Mizushima, N., Mizuta, T., Arakawa-Kobayashi, S., Thompson, C. B., & Tsujimoto, Y. (2004) · Nature Cell Biology · doi:10.1038/ncb1192 · Cited by 1,358
Weng, W.-K., & Levy, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.013 · Cited by 1,300
Molecular dissection of autophagy: two ubiquitin-like systems
Ohsumi, Y. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35056522 · Cited by 1,240
Potent antibody therapeutics by design
Carter, P. J. (2006) · Nature Reviews Immunology · doi:10.1038/nri1837 · Cited by 1,099
Autophagy and signaling: their role in cell survival and cell death
Codogno, P., & Meijer, A. J. (2005) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401751 · Cited by 1,092
Fcγ Receptors: Old Friends and New Family Members
Nimmerjahn, F., & Ravetch, J. V. (2006) · Immunity · doi:10.1016/j.immuni.2005.11.010 · Cited by 1,072
Divergent Immunoglobulin G Subclass Activity Through Selective Fc Receptor Binding
Nimmerjahn, F., & Ravetch, J. V. (2005) · Science · doi:10.1126/science.1118948 · Cited by 1,037
Generation of C5a in the absence of C3: a new complement activation pathway
Huber-Lang, M., Sarma, J. V., Zetoune, F. S., Rittirsch, D., Neff, T. A., McGuire, S. R., Lambris, J. D., Warner, R. L., Flierl, M. A., Hoesel, L. M., et al. (2006) · Nature Medicine · doi:10.1038/nm1419 · Cited by 975
Improving the efficacy of antibody-based cancer therapies
Carter, P. (2001) · Nature Reviews Cancer · doi:10.1038/35101072 · Cited by 833
Engineered antibody Fc variants with enhanced effector function
Lazar, G. A., Dang, W., Karki, S., Vafa, O., Peng, J. S., Hyun, L., Chan, C., Chung, H. S., Eivazi, A., Yoder, S. C., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508123103 · Cited by 803
Uchida, J., Hamaguchi, Y., Oliver, J. A., Ravetch, J. V., Poe, J. C., Haas, K. M., & Tedder, T. F. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20040119 · Cited by 642
Teeling, J. L. (2004) · Blood · doi:10.1182/blood-2004-01-0039 · Cited by 630
Rituximab, an Anti-CD20 Monoclonal Antibody: History and Mechanism of Action
Pescovitz, M. D. (2006) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2006.01288.x · Cited by 625
Regulation and role of autophagy in mammalian cells
Meijer, A. J., & Codogno, P. (2004) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2004.02.002 · Cited by 615
The Biological Activity of Human CD20 Monoclonal Antibodies Is Linked to Unique Epitopes on CD20
Teeling, J. L., Mackus, W. J. M., Wiegman, L. J. J. M., van den Brakel, J. H. N., Beers, S. A., French, R. R., van Meerten, T., Ebeling, S., Vink, T., Slootstra, J. W., et al. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.1.362 · Cited by 609
Self-citationGolay, J., Zaffaroni, L., Vaccari, T., Lazzari, M., Borleri, G.-M., Bernasconi, S., Tedesco, F., Rambaldi, A., & Introna, M. (2000) · Blood · doi:10.1182/blood.v95.12.3900 · Cited by 604
Apoptosis of Malignant Human B Cells by Ligation of CD20 With Monoclonal Antibodies
Shan, D., Ledbetter, J. A., & Press, O. W. (1998) · Blood · doi:10.1182/blood.v91.5.1644 · Cited by 576
Complement Activation Determines the Therapeutic Activity of Rituximab In Vivo
Di Gaetano, N., Cittera, E., Nota, R., Vecchi, A., Grieco, V., Scanziani, E., Botto, M., Introna, M., & Golay, J. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.3.1581 · Cited by 576
Importance of Cellular Microenvironment and Circulatory Dynamics in B Cell Immunotherapy
Gong, Q., Ou, Q., Ye, S., Lee, W. P., Cornelius, J., Diehl, L., Lin, W. Y., Hu, Z., Lu, Y., Chen, Y., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.2.817 · Cited by 543
Autophagy and related mechanisms of lysosome-mediated protein degradation
Dunn, W. A. (1994) · Trends in Cell Biology · doi:10.1016/0962-8924(94)90069-8 · Cited by 521
B-cell targeting in rheumatoid arthritis and other autoimmune diseases
Edwards, J. C. W., & Cambridge, G. (2006) · Nature Reviews Immunology · doi:10.1038/nri1838 · Cited by 507
Hong, F., Yan, J., Baran, J. T., Allendorf, D. J., Hansen, R. D., Ostroff, G. R., Xing, P. X., Cheung, N.-K. V., & Ross, G. D. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.2.797 · Cited by 472
Hoyer, B. F., Moser, K., Hauser, A. E., Peddinghaus, A., Voigt, C., Eilat, D., Radbruch, A., Hiepe, F., & Manz, R. A. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20040168 · Cited by 440
Rituximab-Dependent Cytotoxicity by Natural Killer Cells
Dall’Ozzo, S., Tartas, S., Paintaud, G., Cartron, G., Colombat, P., Bardos, P., Watier, H., & Thibault, G. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2862 · Cited by 434
Anolik, J. H., Campbell, D., Felgar, R. E., Young, F., Sanz, I., Rosenblatt, J., & Looney, R. J. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10764 · Cited by 429
Golay, J., Lazzari, M., Facchinetti, V., Bernasconi, S., Borleri, G., Barbui, T., Rambaldi, A., & Introna, M. (2001) · Blood · doi:10.1182/blood.v98.12.3383 · Cited by 428
Mapping of the C1q Binding Site on Rituxan, a Chimeric Antibody with a Human IgG1 Fc
Idusogie, E. E., Presta, L. G., Gazzano-Santoro, H., Totpal, K., Wong, P. Y., Ultsch, M., Meng, Y. G., & Mulkerrin, M. G. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.8.4178 · Cited by 424
Cell Surface Recycling of Internalized Antigen Permits Dendritic Cell Priming of B Cells
Bergtold, A., Desai, D. D., Gavhane, A., & Clynes, R. (2005) · Immunity · doi:10.1016/j.immuni.2005.09.013 · Cited by 401
Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts
Cragg, M. S., Morgan, S. M., Chan, H. T. C., Morgan, B. P., Filatov, A. V., Johnson, P. W. M., French, R. R., & Glennie, M. J. (2003) · Blood · doi:10.1182/blood-2002-06-1761 · Cited by 390
Self-citationSignaling events involved in anti-CD20-induced apoptosis of malignant human B cells
Shan, D., Ledbetter, J. A., & Press, O. W. (2000) · Cancer Immunology, Immunotherapy · doi:10.1007/s002620050016 · Cited by 385
In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas
Manches, O., Lui, G., Chaperot, L., Gressin, R., Molens, J.-P., Jacob, M.-C., Sotto, J.-J., Leroux, D., Bensa, J.-C., & Plumas, J. (2003) · Blood · doi:10.1182/blood-2002-02-0469 · Cited by 372
Byrd, J. C., Kitada, S., Flinn, I. W., Aron, J. L., Pearson, M., Lucas, D., & Reed, J. C. (2002) · Blood · doi:10.1182/blood.v99.3.1038 · Cited by 367
The Biology of CD20 and Its Potential as a Target for mAb Therapy
Cragg, M. S., Walshe, C. A., Ivanov, A. O., & Glennie, M. J. (2004) · Current Directions in Autoimmunity · doi:10.1159/000082102 · Cited by 364
Self-citationAntibody specificity controls in vivo effector mechanisms of anti-CD20 reagents
Cragg, M. S., & Glennie, M. J. (2004) · Blood · doi:10.1182/blood-2003-06-2031 · Cited by 360
Self-citationKennedy, A. D., Beum, P. V., Solga, M. D., DiLillo, D. J., Lindorfer, M. A., Hess, C. E., Densmore, J. J., Williams, M. E., & Taylor, R. P. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.5.3280 · Cited by 359
Self-citationImmunotoxin Treatment of Cancer
Pastan, I., Hassan, R., FitzGerald, D. J., & Kreitman, R. J. (2007) · Annual Review of Medicine · doi:10.1146/annurev.med.58.070605.115320 · Cited by 359
Bubien, J. K., Zhou, L. J., Bell, P. D., Frizzell, R. A., & Tedder, T. F. (1993) · The Journal of cell biology · doi:10.1083/jcb.121.5.1121 · Cited by 355
Dyer, M., Hale, G., Hayhoe, F., & Waldmann, H. (1989) · Blood · doi:10.1182/blood.v73.6.1431.1431 · Cited by 349
Rituximab therapy of patients with B-cell chronic lymphocytic leukemia
Huhn, D. (2001) · Blood · doi:10.1182/blood.v98.5.1326 · Cited by 347
Parren, P. W., Warmerdam, P. A., Boeije, L. C., Arts, J., Westerdaal, N. A., Vlug, A., Capel, P. J., Aarden, L. A., & van de Winkel, J. G. (1992) · Journal of Clinical Investigation · doi:10.1172/jci116022 · Cited by 346
Complement activation plays a key role in the side‐effects of rituximab treatment
Van Der Kolk, L. E., Grillo‐López, A. J., Baars, J. W., Hack, C. E., & Van Oers, M. H. J. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.03166.x · Cited by 327
Bindon, C. I., Hale, G., Brüggemann, M., & Waldmann, H. (1988) · The Journal of experimental medicine · doi:10.1084/jem.168.1.127 · Cited by 292
Engineered Antibodies with Increased Activity to Recruit Complement
Idusogie, E. E., Wong, P. Y., Presta, L. G., Gazzano-Santoro, H., Totpal, K., Ultsch, M., & Mulkerrin, M. G. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.4.2571 · Cited by 291
Shushakova, N., Skokowa, J., Schulman, J., Baumann, U., Zwirner, J., Schmidt, R. E., & Gessner, J. E. (2002) · Journal of Clinical Investigation · doi:10.1172/jci16577 · Cited by 284
Anti‐dsdna and complement profiles as prognostic guides in systemic lupus erythematosus
Swaak, A. J. G., Aarden, L. A., Statius Eps, L. W. V., & Feltkamp, T. E. W. (1979) · Arthritis & Rheumatism · doi:10.1002/art.1780220304 · Cited by 284
Therapeutic intervention with complement and β-glucan in cancer
Ross, G. D., Větvička, V., Yan, J., Xia, Y., & Větvičková, J. (1999) · Immunopharmacology · doi:10.1016/s0162-3109(99)00013-2 · Cited by 283
Hatjiharissi, E., Xu, L., Santos, D. D., Hunter, Z. R., Ciccarelli, B. T., Verselis, S., Modica, M., Cao, Y., Manning, R. J., Leleu, X., et al. (2007) · Blood · doi:10.1182/blood-2007-01-070656 · Cited by 282
Treon, S. P., Hansen, M., Branagan, A. R., Verselis, S., Emmanouilides, C., Kimby, E., Frankel, S. R., Touroutoglou, N., Turnbull, B., Anderson, K. C., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.059 · Cited by 263
Complement function in mAb-mediated cancer immunotherapy
Gelderman, K. A., Tomlinson, S., Ross, G. D., & Gorter, A. (2004) · Trends in Immunology · doi:10.1016/j.it.2004.01.008 · Cited by 262
van Meerten, T., van Rijn, R. S., Hol, S., Hagenbeek, A., & Ebeling, S. B. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0066 · Cited by 250
Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies.
Press, O. W., Farr, A. G., Borroz, K. I., Anderson, S. K., & Martin, P. J. (1989) · PubMed · Cited by 248
Kipps, T. J., Parham, P., Punt, J., & Herzenberg, L. A. (1985) · The Journal of experimental medicine · doi:10.1084/jem.161.1.1 · Cited by 248
The mechanisms of action of rituximab in the elimination of tumor cells
Johnson, P., & Glennie, M. (2003) · Seminars in Oncology · doi:10.1053/sonc.2003.50025 · Cited by 247
Self-citationBeum, P. V., Kennedy, A. D., Williams, M. E., Lindorfer, M. A., & Taylor, R. P. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.4.2600 · Cited by 239
Self-citationHamaguchi, Y., Xiu, Y., Komura, K., Nimmerjahn, F., & Tedder, T. F. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20052283 · Cited by 237
Antibodies, Fc receptors and cancer
Nimmerjahn, F., & Ravetch, J. V. (2007) · Current Opinion in Immunology · doi:10.1016/j.coi.2007.01.005 · Cited by 234
CD20‐mediated apoptosis: signalling through lipid rafts
Deans, J. P., Li, H., & Polyak, M. J. (2002) · Immunology · doi:10.1046/j.1365-2567.2002.01495.x · Cited by 233
Bowles, J. A., Wang, S.-Y., Link, B. K., Allan, B., Beuerlein, G., Campbell, M.-A., Marquis, D., Ondek, B., Wooldridge, J. E., Smith, B. J., et al. (2006) · Blood · doi:10.1182/blood-2006-04-020057 · Cited by 227
Predictive value of complement profiles and anti-dsDNA in systemic lupus erythematosus.
Swaak, A. J., Groenwold, J., & Bronsveld, W. (1986) · Annals of the Rheumatic Diseases · doi:10.1136/ard.45.5.359 · Cited by 224
Pathogenic Roles of B Cells in Human Autoimmunity
Martin, F., & Chan, A. C. (2004) · Immunity · doi:10.1016/s1074-7613(04)00112-8 · Cited by 224
Hofmeister, J. K., Cooney, D., & Coggeshall, K. M. (2000) · Blood Cells, Molecules, and Diseases · doi:10.1006/bcmd.2000.0287 · Cited by 222
Pedersen, I. M., Buhl, A. M., Klausen, P., Geisler, C. H., & Jurlander, J. (2002) · Blood · doi:10.1182/blood.v99.4.1314 · Cited by 219
Weng, W.-K., & Levy, R. (2001) · Blood · doi:10.1182/blood.v98.5.1352 · Cited by 218
Xia, M. Q., Hale, G., Lifely, M. R., Ferguson, M. A. J., Campbell, D., Packman, L., & Waldmann, H. (1993) · Biochemical Journal · doi:10.1042/bj2930633 · Cited by 213
Hamaguchi, Y., Uchida, J., Cain, D. W., Venturi, G. M., Poe, J. C., Haas, K. M., & Tedder, T. F. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.7.4389 · Cited by 212
Chan, H. T. C., Hughes, D., French, R. R., Tutt, A. L., Walshe, C. A., Teeling, J. L., Glennie, M. J., & Cragg, M. S. (2003) · PubMed · Cited by 211
Self-citationTreon, S. P., Mitsiades, C., Mitsiades, N., Young, G., Doss, D., Schlossman, R., & Anderson, K. C. (2001) · Journal of Immunotherapy · doi:10.1097/00002371-200105000-00011 · Cited by 205
Ghetie, M.-A., Bright, H., & Vitetta, E. S. (2001) · Blood · doi:10.1182/blood.v97.5.1392 · Cited by 191
M. Cardarelli, M. Q. (2002) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-001-0247-1 · Cited by 189
Van Rooijen, N., & Sanders, A. (1996) · Hepatology · doi:10.1002/hep.510230544 · Cited by 188
Carnahan, J. F., Wang, P., Kendall, R. L., Chen, C., Hu, S., Boone, T., Juan, T., Talvenheimo, J., Montestruque, S., Sun, J., et al. (2003) · PubMed · Cited by 185
Fossati-Jimack, L., Ioan-Facsinay, A., Reininger, L., Chicheportiche, Y., Watanabe, N., Saito, T., Hofhuis, F. M. A., Gessner, J. E., Schiller, C., Schmidt, R. E., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.8.1293 · Cited by 180
Golay, J. T., Clark, E. A., & Beverley, P. C. (1985) · The Journal of Immunology · doi:10.4049/jimmunol.135.6.3795 · Cited by 175
Fc receptors and their interaction with complement in autoimmunity
Schmidt, R. E., & Gessner, J. E. (2005) · Immunology Letters · doi:10.1016/j.imlet.2005.06.022 · Cited by 174
Davis, T. A., Maloney, D. G., Czerwinski, D. K., Liles, T.-M., & Levy, R. (1998) · Blood · doi:10.1182/blood.v92.4.1184 · Cited by 174
Polyak, M. J., & Deans, J. P. (2002) · Blood · doi:10.1182/blood.v99.9.3256 · Cited by 159
Mathas, S., Rickers, A., Bommert, K., Dörken, B., & Mapara, M. Y. (2000) · PubMed · Cited by 155
Acquisition of Viral Receptor by NK Cells Through Immunological Synapse
Tabiasco, J., Vercellone, A., Meggetto, F., Hudrisier, D., Brousset, P., & Fournié, J. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.12.5993 · Cited by 151
Rapid Redistribution of CD20 to a Low Density Detergent-insoluble Membrane Compartment
Deans, J. P., Robbins, S. M., Polyak, M. J., & Savage, J. A. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.1.344 · Cited by 151
Williams, M. E., Densmore, J. J., Pawluczkowycz, A. W., Beum, P. V., Kennedy, A. D., Lindorfer, M. A., Hamil, S., Eggleton, J. C., & Taylor, R. P. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.10.7435 · Cited by 148
Self-citationCD16 polymorphisms and NK activation induced by monoclonal antibody-coated target cells
Bowles, J. A., & Weiner, G. J. (2005) · Journal of Immunological Methods · doi:10.1016/j.jim.2005.06.018 · Cited by 148
Tedder, T. F., Forsgren, A., Boyd, A., Nadler, L. M., & Schlossman, S. F. (1986) · European Journal of Immunology · doi:10.1002/eji.1830160802 · Cited by 146
IMPORTANCE OF ANTIGEN SPECIFICITY FOR COMPLEMENT‐MEDIATED LYSIS BY MONOCLONAL ANTIBODIES
Bindon, C. I., Hale, G., & Waldmann, H. (1988) · European Journal of Immunology · doi:10.1002/eji.1830181006 · Cited by 145
Kennedy, A. D., Solga, M. D., Schuman, T. A., Chi, A. W., Lindorfer, M. A., Sutherland, W. M., Foley, P. L., & Taylor, R. P. (2003) · Blood · doi:10.1182/blood-2002-03-0876 · Cited by 141
Self-citationBiology and Treatment of Chronic Lymphocytic Leukemia
Keating, M. J., Chiorazzi, N., Messmer, B. T., Damle, R. N., Allen, S. L., Rai, K. R., Ferrarini, M., & Kipps, T. J. (2003) · Hematology · doi:10.1182/asheducation-2003.1.153 · Cited by 131
The therapeutic potential of anti-CD20
Eisenberg, R. A., & Looney, R. J. (2005) · Clinical Immunology · doi:10.1016/j.clim.2005.08.006 · Cited by 129
Glucocorticoids and rituximab in vitro: synergistic direct antiproliferative and apoptotic effects
Rose, A. L., Smith, B. E., & Maloney, D. G. (2002) · Blood · doi:10.1182/blood.v100.5.1765.h81702001765_1765_1773 · Cited by 129
Golay, J., Cittera, E., Gaetano, N. D., Manganini, M., Mosca, M., Nebuloni, M., van Rooijen, N., Vago, L., & Introna, M. (2006) · PubMed · Cited by 129
Meyer, D., Schiller, C., Westermann, J., Izui, S., Hazenbos, W. L. W., Verbeek, J. S., Schmidt, R. E., & Gessner, J. E. (1998) · Blood · doi:10.1182/blood.v92.11.3997 · Cited by 124
Reassessment of the clinical significance of native dna antibodies in systemic lupus erythematosus
Miniter, M. F., Stollar, B. D., & Agnello, V. (1979) · Arthritis & Rheumatism · doi:10.1002/art.1780220903 · Cited by 124
Cell-derived anaphylatoxins as key mediators of antibody-dependent type II autoimmunity in mice
Kumar, V. (2006) · Journal of Clinical Investigation · doi:10.1172/jci25536 · Cited by 118
Leonard, J. P., Friedberg, J. W., Younes, A., Fisher, D. C., Gordon, L. I., Moore, J. O., Czuczman, M. S., Miller, T. P., Stiff, P. J., Cheson, B. D., et al. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm114 · Cited by 118
Yazawa, N., Hamaguchi, Y., Poe, J. C., & Tedder, T. F. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0505539102 · Cited by 115
Golay, J., Manganini, M., Facchinetti, V., Gramigna, R., Broady, R. C., Borleri, G., Rambaldi, A., & Introna, M. (2003) · PubMed · Cited by 113
Desai, D. D., Harbers, S. O., Flores, M., Colonna, L., Downie, M. P., Bergtold, A., Jung, S., & Clynes, R. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.10.6217 · Cited by 112
Monoclonal Antibodies in the Treatment of Non-Hodgkin???s Lymphoma
Fanale, M. A., & Younes, A. (2007) · Drugs · doi:10.2165/00003495-200767030-00002 · Cited by 111
Lefebvre, M.-L., Krause, S. W., Salcedo, M., & Nardin, A. (2006) · Journal of Immunotherapy · doi:10.1097/01.cji.0000203081.43235.d7 · Cited by 111
Perosa, F., Favoino, E., Caragnano, M. A., & Dammacco, F. (2005) · Blood · doi:10.1182/blood-2005-04-1769 · Cited by 110
Rituximab: mechanisms and applications
Johnson, P., & Glennie, M. J. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.2127 · Cited by 103
Self-citationHudrisier, D., Aucher, A., Puaux, A., Bordier, C., & Joly, E. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.6.3637 · Cited by 102
Long‐Lived Plasma Cells and Their Contribution to Autoimmunity
Hoyer, B. F., Manz, R. A., Radbruch, A., & Hiepe, F. (2005) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1313.014 · Cited by 101
Bevaart, L., Jansen, M., van Vugt, M. J., Verbeek, J. S., van de Winkel, J. G. J., & Leusen, J. H. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2856 · Cited by 97
Antibodies to DNA. A perspective
Emlen, W., Pisetsky, D. S., & Taylor, R. P. (1986) · Arthritis & Rheumatism · doi:10.1002/art.1780291201 · Cited by 96
Self-citationDavis, W., Harrison, P. T., Hutchinson, M. J., & Allen, J. M. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb07019.x · Cited by 95
Løvdal, T., Andersen, E., Brech, A., & Berg, T. (2000) · Journal of Cell Science · doi:10.1242/jcs.113.18.3255 · Cited by 93
Petrie, R. J., & Deans, J. P. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.6.2886 · Cited by 93
CD20-induced B cell death can bypass mitochondria and caspase activation
van der Kolk, L., Evers, L. M., Omene, C. O., Lens, S. M. A., Lederman, S. M., van Lier, R. A. W., van Oers, M., & Eldering, E. (2002) · Leukemia · doi:10.1038/sj.leu.2402559 · Cited by 90
Depletion of B Cells by a Humanized Anti-CD20 Antibody PRO70769 in Macaca Fascicularis
Vugmeyster, Y., Beyer, J. C., Howell, K., Combs, D., Fielder, P. J., Yang, J., Qureshi, F., Sandlund, B., Kawaguchi, L., Dummer, W., et al. (2005) · Journal of Immunotherapy · doi:10.1097/01.cji.0000155050.03916.04 · Cited by 79
Rituximab therapy of lymphoma is enhanced by orally administered (1→3),(1→4)-d-β-glucan
Modak, S. I., Koehne, G., Vickers, A. J., O’Reilly, R. J., & Cheung, N. V. (2005) · Leukemia Research · doi:10.1016/j.leukres.2004.10.008 · Cited by 74
Rituximab: perspective on single agent experience, and future directions in combination trials
McLaughlin, P. J. (2001) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(01)00130-5 · Cited by 71
Clark, E. A., & Shu, G. L. (1987) · The Journal of Immunology · doi:10.4049/jimmunol.138.3.720 · Cited by 66
Shan, D., Press, O. W., Tsu, T. T., Hayden, M. S., & Ledbetter, J. A. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.11.6589 · Cited by 63
Tedder, T. F., Baras, A., & Xiu, Y. (2006) · Springer Seminars in Immunopathology · doi:10.1007/s00281-006-0057-9 · Cited by 62
Monoclonal antibody as therapy for malignant lymphomas
Coiffier, B. (2006) · Comptes Rendus Biologies · doi:10.1016/j.crvi.2005.12.006 · Cited by 57
Umaña, P., Moessner, E., Brünker, P., Unsin, G., Püntener, U., Suter, T. B., Grau, R., Schmidt, C., Gerdes, C. A., Nopora, A., et al. (2006) · Blood · doi:10.1182/blood.v108.11.229.229 · Cited by 53
Jaekel, H.-P., Trabandt, A., Grobe, N., & Werle, E. (2006) · Lupus · doi:10.1191/0961203306lu2308oa · Cited by 43
A Review of Antibody Therapeutics and Antibody-Related Technologies for Oncology
Scallon, B. J., Snyder, L. A., Anderson, G. M., Chen, Q., Li, Y., Weiner, L. M., & Nakada, M. T. (2006) · Journal of Immunotherapy · doi:10.1097/01.cji.0000199196.97845.c3 · Cited by 38
Klepfish, A., Schattner, A., Ghoti, H., & Rachmilewitz, E. A. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70106-7 · Cited by 36
Ivanov, A., Krysov, S. V., Cragg, M. S., & Illidge, T. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5072 · Cited by 35
Self-citationde Menezes, D. E. L., Denis-Mize, K. S., Tang, Y., Ye, H., Kunich, J. C., Garrett, E. N., Peng, J., Cousens, L. S., Gelb, A. B., Heise, C. C., et al. (2006) · Journal of Immunotherapy · doi:10.1097/01.cji.0000211315.21116.07 · Cited by 30
Immunology of DNA. V. Analysis of DNA/anti-DNA complexes
Aarden, L. A., de Groot, E. R., & Lakmaker, F. (1976) · Journal of Immunological Methods · doi:10.1016/0022-1759(76)90071-5 · Cited by 29
C5a and Fc receptors: a mutual admiration society
Atkinson, J. P. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27759 · Cited by 28
Ermini, L., Secciani, F., Sala, G. B. L., et al. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.10.082 · Cited by 23
Chan, H. T. C., Wang, J., French, R. R., & Glennie, M. J. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.43.27809 · Cited by 19
Self-citationMack, D. A., Beum, P. V., Lindorfer, M. A., Pawluczkowycz, A. W., & Taylor, R. P. (2006) · Blood · doi:10.1182/blood.v108.11.2096.2096 · Cited by 2
Self-citation
Cited by
Chao, M. P., Alizadeh, A. A., Tang, C., Myklebust, J. H., Varghese, B., Gill, S., Jan, M., Cha, A. C., Chan, C. K., Tan, B. T., et al. (2010) · Cell · doi:10.1016/j.cell.2010.07.044 · Cited by 1,087
Development trends for human monoclonal antibody therapeutics
Nelson, A. L., Dhimolea, E., & Reichert, J. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3229 · Cited by 1,026
Mössner, E., Brünker, P., Moser, S., Püntener, U., Schmidt, C., Herter, S., Grau, R., Gerdes, C., Nopora, A., van Puijenbroek, E., et al. (2010) · Blood · doi:10.1182/blood-2009-06-225979 · Cited by 981
Building better monoclonal antibody-based therapeutics
Weiner, G. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3930 · Cited by 712
Complement in Immune and Inflammatory Disorders: Pathophysiological Mechanisms
Ricklin, D., & Lambris, J. D. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1203487 · Cited by 478
Metadata
- Authors
- Glennie, M. J., French, R. R., Cragg, M. S., & Taylor, R. P.
- Venue
- Molecular Immunology
- Publisher
- Elsevier BV
- Published
- 2007-09
- Volume
- 44
- Issue
- 16
- Pages
- 3823-3837
- ISSN
- 0161-5890 (ISSN-L)
- OpenAlex
- W1996710470
- Cited by
- 515
- References
- 136
- FWCI
- 25.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.